MEDIA KIT

The Quotient media kit is designed to help journalists research our company for background information or follow-up stories. Please contact us if you need more detailed information or to schedule interviews.

Approved imagery

Browse through our approved corporate photos. These images may be used for editorial purposes as long as the connection to Quotient is clearly recognizable. Commercial use is prohibited.

1
2
3
4
5
Image Caption Size Download
1 Hand, close-up of microarray 2.1 MB JPG
2 MosaiQ by Quotient instrument and lab technician 2.5 MB JPG
3 MosaiQ by Quotient instrument and microarray cartridge loading dock 2.3 MB JPG
4 Lab technicians blood sample, lab 2.5 MB JPG
5 MosaiQ COVID-19 Antibody Microarray 6.0 MB MP4
6 MosaiQ COVID-19 Antibody Microarray Infographic 0.2 MB PDF

 

Approved company descriptions

75 words

Quotient is a commercial-stage diagnostics company committed to delivering solutions that reshape the way diagnostics is practiced. Quotient has two key product portfolios, Alba by Quotient, quality blood bank reagents used in laboratories around the world, and MosaiQ™ by Quotient, the world’s first fully automated, consolidated testing platform. In response to the global effort to combat COVID-19, Quotient developed MosaiQ COVID-19 Antibody Microarray which is CE marked and has received the U.S. FDA Emergency Use Authorization.

150 words

Building on over 30 years of experience in transfusion diagnostics, Quotient is a commercial-stage diagnostics company committed to delivering solutions that reshape the way diagnostics is practiced. MosaiQ, Quotient’s proprietary multiplex microarray technology, offers the world’s first fully automated, consolidated testing platform, allowing for multiple tests across different modalities. MosaiQ is designed to be a game-changing solution, which Quotient believes will increase efficiencies, improve clinical practice, deliver significant workflow improvements, and operational cost savings to laboratories around the world. A serological test was developed in April 2020 in response to the global COVID-19 pandemic. The MosaiQ COVID-19 Antibody Microarray is CE marked and is the subject of an Emergency Use Authorization issued by the U.S. Food and Drug Administration.  The COVID-19 antibody test is available for distribution in the U.S., the EU, the UK and Switzerland. Quotient's operations are based in Eysins, Switzerland, Edinburgh, Scotland and Newtown, Pennsylvania.

Meet our management team

We have over 30 years’ experience manufacturing and supplying conventional reagent products used for blood grouping within the $3.4 billion global transfusion diagnostics market. We are developing MosaiQ by Quotient, our proprietary technology platform, to better address the comprehensive needs of this large and established market. We believe MosaiQ has the potential to be a transformative technology, significantly reducing the cost of blood grouping in the donor and patient testing environments, while improving patient outcomes.

Manuel O. Méndez, Chief Executive Officer

Manuel O. Méndez

Manuel O. Méndez joined Quotient (NASDAQ:QTNT)  as the company’s Chief Executive Officer in April 2021. 

He brings over 30 years of experience in the diagnostics and life science markets. Mr. Méndez joins Quotient from Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services where he served as the Senior Vice President and Chief Commercial Officer. He played a key role in accelerating growth and supporting the COVID-19 efforts.  Before joining Quest, he was living in Germany and served as SVP and Head of Global Commercial Operations and a member of QIAGEN N.V. Executive Committee, a worldwide provider of Sample to Insight solutions for molecular testing. Manuel has held a variety of senior leadership roles with Abbott Laboratories, Thermo Fisher Scientific, OraSure Technologies, and bioMerieux – living in the United States, Europe, Asia, and Latin America.

An American citizen, Mr. Méndez received an MBA from Northwestern University's Kellogg School of Management and a bachelor's degree in biomedical engineering from Boston University. 

Peter Buhler, Chief Financial Officer

Peter Buhler

Peter Buhler joined Quotient (NASDAQ:QTNT) as the company’s Chief Financial Officer in February 2020. Mr Buhler has more than 20 years of experience in the strategic and financial leadership of life science and technology businesses in both the public and private sectors, more recently with Zaluvida AG, where he served as Group Chief Financial Officer.

In addition, Mr Buhler served as Group Chief Financial Officer of Greer Plc, a global leader in allergy immunotherapy headquartered in London.

While there, Mr Buhler led a complex merger project to combine a French and a US Group through the creation of a UK holding. Previously, he served as Head of Finance, Commercial Europe at Merck Serono SA and Finance Director EMEA at Logitech SA.

He is a Swiss Certified Accountant and an Executive MBA from the Swiss Business School in Zurich.

Jeremy Stackawitz, Chief Commercial Officer

Jeremy Stackawitz

Jeremy Stackawitz joined Quotient (NASDAQ:QTNT) 10 years ago, overseeing the company through a period of sustained rapid growth. He led Quotient’s entry into the US market, where the company now serves over 1,000 customers and has successfully obtained over 60 FDA product approvals. He currently serves as President of Commercial and the Reagent Business.

He brings over 20 years of experience in healthcare, including diagnostics, pharmaceuticals and biotechnology. His past experiences include serving in various business development, general management and commercial roles for Johnson & Johnson, which included Commercial Director of Immunohematology for Ortho Clinical Diagnostics.

Previously he worked at Purdue Pharma running various Market Research and Commercial groups, and served as a Strategy Consultant to the healthcare industry with Monitor and McKinsey & Co consultancies.

Mr Stackawitz holds a BA in Chemistry from Dartmouth College and an MBA in Healthcare Management from The Wharton School, University of Pennsylvania.

Office locations

Global (HQ)

Quotient Suisse SA

B1, Business Park Terre Bonne
Route de Crassier 13
Eysins, 1262
Switzerland

UK

Quotient

5 James Hamilton Way
Milton Bridge
Penicuik EH26 0BF
United Kingdom

USA

Quotient

301 S State St
Newtown, PA 18940-1997
United States

Social

We are proud to be active and responsive on Twitter and LinkedIn.
Follow us to stay updated on Quotient news, announcements & updates.

 

Twitter

@QuotientHQ

 

LinkedIn

QuotientLtd

Social